NICE consultation on kidney cancer drugs
The National Institute for Health and Clinical Excellence has recommended that bevacizumab, sorafenib, sunitinib and temsirolimus should not be treatment options for advanced or metastatic renal cell carcinoma.
Subscriber only content
You must be a paid subscriber to Health Service Journal magazine to read this article and receive complete, unrestricted access to hsj.co.uk
HSJ Subscribers:
If you are a Health Service Journal subscriber please sign in with your email address and click submit:
Internet Explorer users - please use the "Sign in" link near the top right of the page to ensure you are automatically remembered when returning to the site
Not a HSJ subscriber?
Choose one of these options:
Subscribe today for immediate access to hsj.co.uk and Health Service Journal magazine at a special introductory rate
Find out more about all the benefits of a subscription to Health Service Journal by clicking below
